Genomes and Genes


Miguel Angel Calleja


Country: Spain


  1. Garrido P, Aldaz A, Calleja M, de Alava E, Lamas M, Martin M, et al. Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: a position statement of SEOM, SEAP and SEFH. Farm Hosp. 2017;41:688-691 pubmed publisher
  2. Calleja Hernández M, Herrero Ambrosio A, Lamas Díaz M, Martínez Cutillas J, Poveda Andrés J, Aragón B. Pharmacotherapy follow-up of patients under treatment with biologic agents for chronic inflammatory systemic conditions: an agreement among hospital pharmacists for the standardized collection of a minimum set of data. Farm Hosp. 2017;41:31-48 pubmed publisher
  3. Garrido P, Aldaz A, Calleja M, de Alava E, Lamas M, Martin M, et al. [Proposal of the SEOM, SEAP and SEFH for the creation of a National Strategy for Precision Medicine in Cancer]. Rev Esp Patol. 2018;51:154-159 pubmed publisher
  4. Sanchez Rodriguez E, Lima Cabello E, Biel Glesson S, Fernandez Navarro J, Calleja M, Roca M, et al. Effects of Virgin Olive Oils Differing in Their Bioactive Compound Contents on Metabolic Syndrome and Endothelial Functional Risk Biomarkers in Healthy Adults: A Randomized Double-Blind Controlled Trial. Nutrients. 2018;10: pubmed publisher
    ..No effect of triterpenes was observed after three weeks of interventions. Results need to be confirmed in subjects with metabolic syndrome and impaired endothelial function (Clinical Trials number NCT02520739). ..
  5. Madrid Paredes A, Cañadas Garre M, Sánchez Pozo A, Segura Pérez A, Chamorro Santos C, Vergara Alcaide E, et al. ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients. Pharmacol Res. 2016;108:111-118 pubmed publisher
    ..Although this study demonstrates a prognostic value of ABCB1-C3435T gene polymorphism to predict clinical outcomes, further studies with a larger sample will be necessary to validate this result. ..
  6. Madrid Paredes A, Cañadas Garre M, Sánchez Pozo A, Calleja Hernández M. Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer. Breast Cancer Res Treat. 2015;153:493-505 pubmed publisher
    ..However, the prognostic value of most of the biomarkers investigated to date, such as HER3, IGF1R, PIK3CA, or AKT1 cannot be fully established yet, since results have not been conclusive. ..
  7. Maldonado Montoro M, Cañadas Garre M, González Utrilla A, Plaza Plaza J, Calleja Hernández M. Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis. Pharmacol Res. 2016;111:264-271 pubmed publisher
  8. Pérez Ramírez C, Cañadas Garre M, Molina M, Robles A, Faus Dáder M, Calleja Hernández M. Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer. Mutat Res. 2017;771:32-58 pubmed publisher
    ..Some polymorphisms have been reported to be associated with toxicity or clinical outcome, but data generally come from a limited number of studies and need to be confirmed. ..
  9. Garrido P, Aldaz A, Vera R, Calleja M, de Alava E, Martin M, et al. Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH. Clin Transl Oncol. 2018;20:443-447 pubmed publisher

More Information


  1. Linares Pineda T, Cañadas Garre M, Sánchez Pozo A, Calleja Hernández M. Gene polymorphisms as predictors of response to biological therapies in psoriasis patients. Pharmacol Res. 2016;113:71-80 pubmed publisher
    ..In this article, we will review the influence of gene polymorphisms investigated to date on response to biological drugs in psoriasis patients. ..
  2. request reprint
    Pérez Moreno M, Cotrina Luque J, Galván Banqueri M, Flores Moreno S, Bautista Paloma F, Calleja Hernández M. Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System. Farm Hosp. 2016;40:477-485 pubmed
    ..El perfil de toxicidad fue bien tolerado. Serían necesarios estudios prospectivos para confirmar el efecto de los factores pronósticos observados. ..
  3. Pérez Ramírez C, Cañadas Garre M, Alnatsha A, Villar E, Delgado J, Faus Dáder M, et al. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients. Pharmacol Res. 2016;111:877-884 pubmed publisher
    ..In conclusion, ERCC1 C118T, ERCC2 rs50872, ERCC2 Asp312Asn, ABCB1 C1236T, IL1B rs12621220 and IL16 rs7170924 polymorphisms may substantially act as prognostic factors in NSCLC patients treated with platinum-based chemotherapy. ..
  4. Pérez Ramírez C, Cañadas Garre M, Alnatsha A, Molina M, Robles A, Villar E, et al. Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer. Surg Oncol. 2017;26:278-285 pubmed publisher
    ..No influence of IL1B rs12621220, IL1B rs1143623, IL1B rs16944, IL1B rs1143627, IL6 rs1800795, IL13 rs1881457 on NSCLC clinical outcomes was found in our patients. ..
  5. Pozo O, Pujadas M, Gleeson S, Mesa García M, Pastor A, Kotronoulas A, et al. Liquid chromatography tandem mass spectrometric determination of triterpenes in human fluids: Evaluation of markers of dietary intake of olive oil and metabolic disposition of oleanolic acid and maslinic acid in humans. Anal Chim Acta. 2017;990:84-95 pubmed publisher
    ..Samples from two healthy volunteers who received virgin olive oils with different triterpenes content were analyzed. Some preliminary clues on the metabolic disposition of OA and MA after olive oil intake are provided. ..
  6. Madrid Paredes A, Cañadas Garre M, Sánchez Pozo A, Exposito Ruiz M, Calleja Hernández M. ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: A meta-analysis. Surg Oncol. 2017;26:473-482 pubmed publisher
    ..The available evidence indicates that three polymorphisms within ABCB1; C3435T, C1236T and G2677T/A, cannot be considered a reliable predictor of response to chemotherapy in BC patients. ..
  7. Pérez Ramírez C, Cañadas Garre M, Alnatsha A, Villar E, Delgado J, Calleja Hernández M, et al. Impact of DNA repair, folate and glutathione gene polymorphisms on risk of non small cell lung cancer. Pathol Res Pract. 2018;214:44-52 pubmed publisher
  8. Siquier Homar P, Pinteño Blanco M, Calleja Hernández M, Fernández Cortés F, Martínez Sotelo J. [Development of integrated support software for clinical nutrition]. Farm Hosp. 2015;39:240-68 pubmed publisher
    ..Conclusiones: la aplicacion permite estandarizar el soporte nutricional especializado desde un punto multidisciplinar, introduciendo el concepto de control de calidad por procesos y al paciente como cliente principal. ..
  9. Lozano Blázquez A, Dickson R, Fraga Fuentes M, Martínez Martínez F, Calleja Hernández M. Differences in cancer drug assessment between Spain and the United Kingdom. Eur J Cancer. 2015;51:1843-52 pubmed publisher
    ..Timelines are better for Spanish Committees, probably because of the greater number of steps in the appraisal process by NICE. ..